These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 33145687)

  • 1. Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: a Rapid Review.
    Mackey K; Veazie S; Anderson J; Bourne D; Peterson K
    J Gen Intern Med; 2020 Dec; 35(Suppl 3):954-963. PubMed ID: 33145687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder.
    Haffajee RL; Andraka-Christou B; Attermann J; Cupito A; Buche J; Beck AJ
    Subst Abuse Treat Prev Policy; 2020 Sep; 15(1):69. PubMed ID: 32928272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 4. Managing Acute Pain in Patients Taking Medication for Opioid Use Disorder: a Rapid Review.
    Veazie S; Mackey K; Peterson K; Bourne D
    J Gen Intern Med; 2020 Dec; 35(Suppl 3):945-953. PubMed ID: 33145688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
    Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
    J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
    [No Abstract]   [Full Text] [Related]  

  • 8. Medications for Maintenance Treatment of Opioid Use Disorder in Adolescents: A Narrative Review and Assessment of Clinical Benefits and Potential Risks.
    Camenga DR; Colon-Rivera HA; Muvvala SB
    J Stud Alcohol Drugs; 2019 Jul; 80(4):393-402. PubMed ID: 31495374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Barriers and Facilitators to Implementation of Pharmacotherapy for Opioid Use Disorders in VHA Residential Treatment Programs.
    Finlay AK; Wong JJ; Ellerbe LS; Rubinsky A; Gupta S; Bowe TR; Schmidt EM; Timko C; Burden JL; Harris AHS
    J Stud Alcohol Drugs; 2018 Nov; 79(6):909-917. PubMed ID: 30573022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
    Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
    Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barriers and facilitators to nurse practitioner buprenorphine prescribing for opioid use disorder in primary care settings.
    Speight C; Caiola C; Tyndall DE; Scott ES
    J Am Assoc Nurse Pract; 2023 Feb; 35(2):112-121. PubMed ID: 36512806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication Treatment of Opioid Use Disorder.
    Bell J; Strang J
    Biol Psychiatry; 2020 Jan; 87(1):82-88. PubMed ID: 31420089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014.
    Hadland SE; Wharam JF; Schuster MA; Zhang F; Samet JH; Larochelle MR
    JAMA Pediatr; 2017 Aug; 171(8):747-755. PubMed ID: 28628701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mobile service delivery in response to the opioid epidemic in Philadelphia.
    Stewart RE; Christian HP; Cardamone NC; Abrams C; Drob C; Mandell DS; Metzger D; Lowenstein M
    Addict Sci Clin Pract; 2023 Nov; 18(1):71. PubMed ID: 38031174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics and current clinical practices of opioid treatment programs in the United States.
    Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
    Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Referral to and engagement in substance use disorder treatment within opioid intervention courts in New York: a qualitative study of implementation barriers and facilitators.
    O'Grady MA; Elkington KS; Robson G; Achebe IY; Williams AR; Cohall AT; Cohall R; Christofferson M; Garcia A; Ramsey KS; Lincourt P; Tross S
    Subst Abuse Treat Prev Policy; 2024 Jan; 19(1):12. PubMed ID: 38287329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential barriers to filling buprenorphine and naltrexone prescriptions among a retrospective cohort of individuals with opioid use disorder.
    Morgan JR; Quinn EK; Chaisson CE; Ciemins E; Stempniewicz N; White LF; Larochelle MR
    J Subst Abuse Treat; 2022 Feb; 133():108540. PubMed ID: 34148756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individual, interpersonal, and neighborhood measures associated with opioid use stigma: Evidence from a nationally representative survey.
    Lin Q; Kolak M; Watts B; Anselin L; Pollack H; Schneider J; Taylor B
    Soc Sci Med; 2022 Jul; 305():115034. PubMed ID: 35636049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Barriers and facilitators to buprenorphine use for opioid agonist treatment: protocol for a scoping review.
    Leece P; Khorasheh T; Corace K; Strike C; Bayoumi AM; Taha S; Marks E; Pach B; Ahamad K; Grennell E; Holowaty M; Manson H; Straus SE
    BMJ Open; 2019 Dec; 9(12):e032285. PubMed ID: 31843837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices.
    Andraka-Christou B; Capone MJ
    Int J Drug Policy; 2018 Apr; 54():9-17. PubMed ID: 29324253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.